In-Vitro Diagnostics Patents: Top Companies & Filing Trends 2026
- 18.7% concentration at the top. The five leading assignees account for 6,111 of 32,684 records in scope — a real lead, but not a lock on the field.
- Filings past their 2021 peak. Published filings ran from 909 in 2017 to a peak of 923 in 2021, then fell 56% to 405 by 2024, the last complete year.
- Material analysis dominates the mix. G01N (material analysis & testing) appears on 33.3% of records, well ahead of the peptide, enzyme and medicinal-preparation classes that follow it.
Filing growth compares 2021 (923 records) with 2024 (405) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 32,684 records in scope (CR5), not by the ranked leaders only.
What the in-vitro diagnostics patent record actually shows
In-vitro diagnostics patenting sits at the intersection of assay chemistry, sample-handling instrumentation and the clinical measurement logic that turns a raw signal into a result a physician can act on. The 32,684 records in scope span everything from multiplexed molecular analysis apparatus to risk-stratification algorithms that combine an assay result with an electrocardiogram reading. That range is visible in the IPC composition: G01N material analysis claims sit alongside C07K peptide chemistry and C12Q enzyme- and DNA-based measurement, each occupying a substantial but non-exclusive slice of the corpus.
Filing activity rose through the late 2010s, peaked in 2021, and has declined since — a pattern consistent with a field that built out its core claim space early and is now filling in around it rather than opening new ground at the same pace. Publication lags filing by roughly 18 months, so the most recent one or two years in any trend chart will always look lower than they will eventually settle.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 32,684-record corpus: how filing activity has moved year over year, and how the technology mix breaks down by IPC subclass.
Filing trend, 2017-2026
Published records rose from 909 in 2017 to a peak of 923 in 2021, then fell to 405 by 2024 — a 56% decline over that three-year span. 2025 and 2026 figures are still filling in as publications catch up with filings, so treat the tail of the chart as a floor, not a forecast.
IPC subclass composition
G01N (material analysis & testing) leads at 33.3% of the 32,684 records in scope, followed by C07K peptides & proteins (22.4%), C12Q enzyme/DNA measurement (21.8%) and A61K medicinal preparations (21.3%). Because records can carry multiple IPC classes, these shares add up to more than 100% — they describe overlap, not a partition of the field.
Shares are the percentage of the 32,684 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on In-Vitro Diagnostics Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about in-vitro diagnostics patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this corpus
Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin (NZ543538B)
The claim combines a result from an in-vitro diagnostic assay for ischemia-modified albumin with an electrocardiogram reading, feeding both into an algorithm that outputs a risk stratification for acute cardiac ischemia, acute coronary syndrome, stable or unstable angina.Filed by Ischemia Technologies, Inc., dated 2008-02-08.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5981180A | Multiplexed analysis of clinical specimens apparatus and methods | 1,278 |
| 2 | US5925523A | Intraction trap assay, reagents and uses thereof | 1,144 |
| 3 | US20070061393A1 | Management of health care data | 1,132 |
| 4 | US6200759B1 | Interaction trap assay, reagents and uses thereof | 1,070 |
| 5 | US6083763A | Multiplexed molecular analysis apparatus and method | 873 |
| 6 | US6225047B1 | Use of retentate chromatography to generate difference maps | 812 |
| 7 | US20080040151A1 | Uses of managed health care data | 790 |
| 8 | WO2013006490A2 | Antibodies that specifically bind to tim3 | 753 |
| 9 | US6524793B1 | Multiplexed analysis of clinical specimens apparatus and method | 709 |
| 10 | WO1999023105A1 | VEGI, an inhibitor of angiogenesis and tumor growth | 629 |
Citation counts inside a searched corpus skew toward older filings simply because they have had longer to accumulate citations — read this table as a signal of historical influence, not of what matters today.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern means for strategy
Three read-throughs from the concentration, composition and momentum data, written for a reader deciding where to file or where to license instead of build.
Leadership is real but not exclusionary
The five leading assignees together hold 18.7% of all records in scope, and the top ten extend that to 29.6%. That leaves a long tail of the remaining ranked companies plus unranked filers holding the majority of the corpus — a field with recognisable leaders but no single gatekeeper.
Peak filing has passed, not the field itself
Published filings peaked at 923 in 2021 and fell to 405 by 2024. That decline tracks a corpus that filled its core claim space early; it does not mean assay or instrumentation work has stopped, since publication lag means 2025-2026 counts are still incomplete.
Material analysis is the densest single claim area
G01N material analysis & testing appears on a third of all records, ahead of peptide chemistry, enzyme/DNA measurement and medicinal preparations. A new filer aiming at generic sample-analysis instrumentation is entering the most crowded class in the dataset.
Filing is US-anchored with a thin PCT layer
The United States receives more filings than any other office, with Europe and WIPO's PCT route each carrying a few thousand. Australia, Canada and Singapore trail well behind, suggesting most applicants treat the US as the primary market and file selectively elsewhere.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to in-vitro diagnostics patent landscape, with the prior art for and against each one.
Who is filing, and where they are pulling back
Recent-year momentum figures show several previously active assignees slowing sharply, which opens room for new entrants willing to work the same sub-areas.
A clear leader without a dominant share
The top-ranked assignee holds 2,164 records, well ahead of fifth place at 915 and tenth at 623 — a steep drop-off that signals a genuine leader but a wide field behind it rather than a duopoly.
Several established filers are pulling back sharply
Recent-year momentum shows multiple previously active assignees dropping to single digits or zero filings in the latest tracked year, with year-over-year declines ranging from roughly -13% to -100% across different companies. That pullback does not necessarily mean exit — some of it reflects publication lag — but it does mean less contested ground in the near term.
Co-assignment is concentrated in one relationship
Of 10 identified co-assignee pairs, one relationship accounts for 432 joint records — an order of magnitude above the next strongest pairs. Most other collaboration in this corpus is thin, one-off, or academic-industry in nature rather than a dense partnership network.
| Assignee | Recent year | YoY |
|---|---|---|
| CytomX Therapeutics | 7 | -13% |
| Siemens Healthcare Diagnostics | 3 | -77% |
| Johns Hopkins University | 2 | -83% |
| Human Genome Sciences, Inc. | 0 | — |
| F. Hoffmann-La Roche AG | 0 | — |
| The Regents of the University of California | 0 | -100% |
| Abbott Laboratories | 0 | -100% |
| Roche Diagnostics GmbH | 0 | -100% |
Where to take this next
The dataset points to specific follow-up questions rather than a single answer — use these to decide what to check before committing a filing budget.
Check freedom-to-operate in the under-claimed branches
The white-space chips above sit next to dense claim territory, not inside it. A targeted search in those sub-areas is cheaper than a full landscape and will tell you quickly whether the gap is real.
Explore white space in EurekaWatch the assignees pulling back
Several previously active filers show sharp year-over-year declines. Confirm whether that is a genuine strategic exit or a publication-lag artifact before assuming the ground is clear.
Track assignee momentum in EurekaReassess once 2025-2026 data fills in
The last two years understate real filing activity because publication trails filing by about 18 months. Revisit the trend line once those years are closer to complete.
Set up ongoing monitoring in EurekaCommon questions about the in-vitro diagnostics patent landscape
The five leading assignees together hold 18.7% of the 32,684 records in scope, and the top ten extend that to 29.6%. That is a meaningful lead but far from a lock on the field, since the majority of records sit with the remaining ranked companies and unranked filers. A new entrant should read this as a field with recognisable leaders in specific sub-areas rather than a single gatekeeper controlling the core technology.
Published filings rose from 909 in 2017 to a peak of 923 in 2021, then declined to 405 by 2024, a 56% drop over that three-year span. That decline should not be read as the field slowing down, because publication lags filing by roughly 18 months and the 2025-2026 figures in any current dataset are still incomplete. The more reliable read is that the field filled its densest claim space earlier in the period and filing has settled to a lower but still active rate since.
G01N, covering material analysis and testing, appears on 33.3% of the 32,684 records in scope, the single largest IPC subclass in the dataset. C07K peptide and protein chemistry (22.4%), C12Q enzyme and DNA-based measurement (21.8%), and A61K medicinal preparations (21.3%) follow closely behind. Because a single record can carry several IPC classes, these percentages overlap rather than sum to a whole, and they describe density of claims rather than commercial importance.
NZ543538B claims a method that combines an in-vitro diagnostic assay result — specifically for albumin modified by ischemic tissue exposure — with an electrocardiogram reading, fed through an algorithm to produce a risk stratification for acute cardiac ischemia and related conditions. It also covers an apparatus for that combined diagnosis. Anyone building a multi-signal cardiac risk tool that fuses an assay result with an ECG reading through an algorithmic scoring step should check this claim scope directly rather than assume a different assay chemistry avoids it, since the claim language centres on the combination logic, not a specific biomarker.
The recent-year momentum data shows several previously active assignees dropping sharply — some to zero filings — in the latest tracked year, which loosens contested ground in whatever sub-areas those companies previously worked. Combined with the technology composition figures, sub-areas adjacent to the dense G01N, C07K and C12Q core, such as device-interface claims for point-of-care sample analysis or algorithmic fusion of assay and clinical-measurement data, carry comparatively few dedicated records. A focused freedom-to-operate search in those specific branches is more useful than a broad landscape scan before committing filing budget.
Research In-Vitro Diagnostics Patent Landscape in depth with Eureka
Go past this page: query the whole in-vitro diagnostics patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.